Pacira BioSciences, Inc. (PCRX), Tuesday announced an agreement with LG Chem to expand access to opioid-sparing postsurgical pain control for patients in select Asian-Pacific markets.
Under this deal, LG Chem has the exclusive rights to commercialize EXPAREL, expanding patient access to opioid-sparing pain management.
As per the terms of the deal, Pacira will receive an undisclosed upfront payment, a transfer price, and tiered royalties on future commercial sales by LG Chem in licensed territories.
Notably, LG Chem intends to file for marketing authorizations in South Korea and Thailand within the next six months.
In the pre-market hours, PCRX is trading at $23.13, up 0.87 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.